KPIs & Operating Metrics(New)
Growth Metrics

AbbVie (ABBV) Cash from Investing Activities (2016 - 2026)

AbbVie has reported Cash from Investing Activities over the past 14 years, most recently at -$1.5 billion for Q4 2025.

  • Quarterly Cash from Investing Activities rose 21.93% to -$1.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6.6 billion through Dec 2025, up 68.09% year-over-year, with the annual reading at -$6.6 billion for FY2025, 68.09% up from the prior year.
  • Cash from Investing Activities was -$1.5 billion for Q4 2025 at AbbVie, up from -$3.3 billion in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $1.3 billion in Q3 2022 and troughed at -$9.6 billion in Q1 2024.
  • The 5-year median for Cash from Investing Activities is -$767.5 million (2023), against an average of -$1.6 billion.
  • Year-over-year, Cash from Investing Activities surged 309.11% in 2022 and then tumbled 2137.4% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$1.1 billion in 2021, then skyrocketed by 60.87% to -$448.0 million in 2022, then plummeted by 78.57% to -$800.0 million in 2023, then crashed by 134.25% to -$1.9 billion in 2024, then increased by 21.93% to -$1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Cash from Investing Activities are -$1.5 billion (Q4 2025), -$3.3 billion (Q3 2025), and -$1.2 billion (Q2 2025).